Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Katya Sapunarova"'
Autor:
Silvia Tsvetkova, Katya Doykova, Anna Vasilska, Katya Sapunarova, Daniel Doykov, Vladimir Andonov, Petar Uchikov
Publikováno v:
Diagnostics, Vol 12, Iss 2, p 332 (2022)
Magnetic resonance imaging (MRI) of the breast has been increasingly used for the detailed evaluation of breast lesions. Diffusion-weighted imaging (DWI) gives additional information for the lesions based on tissue cellularity. The aim of our study w
Externí odkaz:
https://doaj.org/article/7a977e57bc904881bb31b64fe32291c0
Publikováno v:
Folia Medica, Vol 62, Iss 2, Pp 265-270 (2020)
Background: Management of beta-thalassemia major (TM) requires life-long hemotransfusions leading to iron overload. Iron elimination is enhanced by the use of modern chelators. Aim: To assess the effect of modern chelation therapy by dynamics of seru
Autor:
Silvia Tsvetkova, Katya Doykova, Anna Vasilska, Katya Sapunarova, Daniel Doykov, Vladimir Andonov, Petar Uchikov
Publikováno v:
Diagnostics; Volume 12; Issue 2; Pages: 332
Magnetic resonance imaging (MRI) of the breast has been increasingly used for the detailed evaluation of breast lesions. Diffusion-weighted imaging (DWI) gives additional information for the lesions based on tissue cellularity. The aim of our study w
Autor:
Marcelo Capra, Fangfang Lv, Wei Li, Tongyu Lin, Eduardo Yañez, Jifeng Feng, Aryan Hamed, Xiaoling Li, Toshiki Uchida, Ming-Chung Wang, Koji Izutsu, Antonio Salar, Katya Sapunarova, Guray Saydam, Jan Zaucha, Lidia Mongay Soler, Shalini Chaturvedi, Anjun Cao, Barrett H Childs, Pier Luigi Zinzani, Matthew J Matasar
Publikováno v:
Blood Cancer Discovery. 3:A32-A32
Introduction: In the Phase III CHRONOS-3 trial investigating the efficacy and safety of the PI3K inhibitor copanlisib in combination with rituximab (C+R), superior efficacy in progression-free survival (PFS) was demonstrated vs placebo plus rituximab
Autor:
Aruna Mehra, L. Mongay Soler, Árpád Szomor, Muhit Ozcan, Qingyuan Zhang, Eduardo Yanez, Barrett H. Childs, Jie Jin, P. L. Zinzani, Rinat Galiulin, Florian Hiemeyer, Klaus Geissler, Igor Bondarenko, Ross I. Baker, Toshiki Uchida, Kamal Bouabdallah, Wojciech Jurczak, Anjun Cao, Jifeng Feng, Wei Li, Fangfang Lv, Aryan Hamed, M. Matasar, T. Lin, Mihaela Lazaroiu, Güray Saydam, Katya Sapunarova, Yuankai Shi, Ming-Chung Wang, Marcelo Capra
Publikováno v:
Hematological Oncology. 39
Autor:
Aryan Hamed, Güray Saydam, Muhit Ozcan, Aruna Mehra, Klaus Geissler, Florian Hiemeyer, Yuankai Shi, Toshiki Uchida, Árpád Szomor, Rinat Galiulin, Lidia Mongay Soler, Fangfang Lv, Eduardo Yanez, Igor Bondarenko, Katya Sapunarova, Matthew J. Matasar, Marcelo Capra, Anjun Cao, Jifeng Feng, Pier Luigi Zinzani, Mihaela Lazaroiu, Krimo Bouabdallah, Jie Jin, Wei Li, Qingyuan Zhang, Wojciech Jurczak, T. Lin, Barrett H. Childs, Ming-Chung Wang, Ross Baker
Publikováno v:
The Lancet. Oncology. 22(5)
Background Copanlisib, an intravenous pan-class I PI3K inhibitor, showed efficacy and safety as monotherapy in patients with relapsed or refractory indolent non-Hodgkin lymphoma who had received at least two therapies. The CHRONOS-3 study aimed to as
Autor:
Pencho Georgiev, Tanya Deneva, Vesselina Goranova-Marinova, Zhanet Grudeva-Popova, Silvia Tsvetkova, Katya Sapunarova
Publikováno v:
Ann Med
Aim of the study: To assess serum sclerostin in transfusion-dependent beta-thalassaemia patients versus healthy controls and to examine its associations with bone mineral density, bone metabolism markers and beta thalassaemia alterations. Material an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db69076868d16ad8467d245c7a656bbd
https://europepmc.org/articles/PMC7877979/
https://europepmc.org/articles/PMC7877979/
Autor:
Eduardo Yanez, Barrett H. Childs, Wojciech Jurczak, Wei Li, Pier Luigi Zinzani, Muhit Ozcan, Matthew J. Matasar, Jie Jin, Anjun Cao, Marcelo Capra, Lidia Mongay Soler, Florian Hiemeyer, Yuankai Shi, Aryan Hamed, Katya Sapunarova, Ming-Chung Wang, Fangfang Lv, Tongyu Lin
Publikováno v:
Blood. 138:3538-3538
Introduction: Copanlisib plus rituximab (C+R) was recently shown to be superior to placebo plus rituximab (P+R) in prolonging progression-free survival in patients with relapsed indolent non-Hodgkin lymphoma (iNHL) (hazard ratio 0.52; 95% confidence
Autor:
Güray Saydam, Árpád Szomor, Toshiki Uchida, Aruna Mehra, Igor Bondarenko, Ming-Chung Wang, Ross I. Baker, Yuankai Shi, Krimo Bouabdallah, Eduardo Yanez, Rinat Galiulin, T. Lin, Jie Jin, Mihaela Lazaroiu, Klaus Geissler, Marcelo Capra, Lidia Mongay Soler, Muhit Ozcan, Fangfang Lv, Katya Sapunarova, Barrett H. Childs, Wei Li, Aryan Hamed, Anjun Cao, Wojciech Jurczak, Jifeng Feng, Florian Hiemeyer, Matthew J. Matasar, Qingyuan Zhang, Pier Luigi Zinzani
Publikováno v:
Cancer Research. 81:CT001-CT001
Introduction: Rituximab (R)-based therapies are standard for patients (pts) with relapsed advanced iNHL. Copanlisib (C) is a PI3K inhibitor approved as monotherapy for relapsed follicular lymphoma (FL) in pts who have had ≥2 prior systemic therapie
Autor:
Eduardo Yanez, Tongyu Lin, Lidia Mongay Soler, Matthew J. Matasar, Pier Luigi Zinzani, Katya Sapunarova, Jie Jin, Barrett H. Childs, Muhit Ozcan, Wei Li, Anjun Cao, Marcelo Capra, Fangfang Lv, Wojciech Jurczak, Aryan Hamed, Charles Phelps, Ming-Chung Wang, Yuankai Shi
Publikováno v:
Journal of Clinical Oncology. 39:7510-7510
7510 Background: Rituximab (R) monotherapy is an approved treatment for patients (pts) with relapsed indolent NHL (iNHL) who have a prolonged progression-free and treatment-free interval after last R-based therapy or who are unwilling/unfit to receiv